Terminal illness and access to phase 1 experimental agents, surgeries and devices: Reviewing the ethical arguments

British Medical Bulletin

Volumn 89, Issue 1, 2009, Pages 7-22

  Schüklenk, Udo ^a   Lowry, Christopher ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Access to experimental drugs; AIDS; HIV; Liberalism, paternalism; Phase 1 trial; PWA; Research ethics; Terminal illness; Therapeutic misconception

Indexed keywords

PLACEBO;

CLINICAL PROTOCOL; CLINICAL RESEARCH; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE ACCESS; HEALTH CARE POLICY; MEDICAL ETHICS; PATIENT DECISION MAKING; PRIORITY JOURNAL; REVIEW; TERMINAL DISEASE; TERMINALLY ILL PATIENT; CLINICAL TRIAL; DRUG INDUSTRY; ETHICS; HEALTH CARE DELIVERY; HUMAN; HUMAN EXPERIMENT; PATIENT RIGHT; TERMINAL CARE;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HUMAN EXPERIMENTATION; HUMANS; PATIENT RIGHTS; TERMINAL CARE; TERMINALLY ILL;

EID: 70349765307     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldn048     Document Type: Review

References (50)

1. Schuklenk U (1998) Access to Experimental Drugs in Terminal Illness: Ethical Issues. New York/London: Pharmaceutical Products Press
2. Schuklenk U (1998) Drug testing and approval in cases of people with catastrophic illness: ethical issues. Clin Res Reg Affairs, 15, 145-157
3. Harris J (2005) Scientific research is a moral duty. J Med Ethics, 31, 242-248
4. Cooper EC (1989) Controlled clinical trials of AIDS drugs: the best hope. J Am Med Assoc, 261, 2445
5. Crimp D (ed) (1988) AIDS: Cultural Analysis, Cultural Activism. Cambridge, MA: MIT Press
6. Centers for Disease Control (CDC) (1982) Update on acquired immune deficiency syndrome (AIDS)-United States. MMWR Morb Mortal Wkly Rep, 31, 507-508; 513-514
7. Epstein S (1995) The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials. Sci Technol Hum Values, 20, 408-437
8. Freedman B (1987) Equipoise and the ethics of clinical research. N Engl J Med, 317, 141-145
9. Schuklenk U, Hogan C (1996) Patient access to experimental drugs and AIDS clinical trial designs. Cam Q Healthc Ethics 5, 400-409
10. Minogue BP, Palmer-Fernandez G, Udell L, Waller PN (1995) Individual autonomy and the double-blind controlled experiment: the case of desperate volunteers. J Med Phil, 20, 43-55
11. Delaney M (1989) The case for patient access to experimental therapy. J Infect Dis, 159, 416-419
12. Delaney M, Novick A (1993) Reflections on a term of public service on the FDA anti-virals advisory committee. AIDS Publ Pol J, 8, 55-61
13. Hellman S, Hellman DS (1991) Of mice but not men: problems of the randomized clinical trial. N Engl J Med, 324, 1585-1589
14. Arras JD (1990) Noncompliance in AIDS research. Hast Cent Rep, 20, 24-32
15. Nussbaum B (1990) Good Intentions: How Big Business and the Medical Establishment Are Corrupting the Fight Against AIDS, Alzheimer's, Cancer and More. New York: Penguin
16. Dworkin G (1988) The Theory and Practice of Autonomy. Cambridge, MA: Cambridge University Press
17. Mill JS (1960) Utilitarianism, Liberty, Representative Government. London: Dent, 73
18. Aristotle (1966) Nicomachean Ethics. Oxford: Oxford University Press
19. Schopenhauer A (1965) On the Basis of Morality. Indianapolis, IN: Bobbs-Merril, 58
20. Mill JS (1960) Utilitarianism, Liberty, Representative Government. London: Dent, 151-152
21. Shorr AF (1992) AIDS and the FDA: an ethical case for limiting patient access to new medical therapies. IRB Rev Hum Subjects Res, 14(June-July), 1-5
22. Wicclair MR (1991) Patient decision-making capacity and risk. Bioethics, 5, 91-104
23. Feinberg J (1986) The Moral Limits of the Criminal Law: Harm to Self. New York: Oxford University Press
24. Buchanan AE, Brock DW (1986) Deciding for others. Milb Q, 64, 17-94
25. Buchholz W (1990) Competent patients and irrational choices. N Engl J Med, 323, 1354-1355
26. Brock DW, Wartman SA (1990) When competent patients make irrational choices. N Engl J Med, 322, 1595-1599
27. Allmark P, Mason S (2006) Should desperate volunteers be included in randomised controlled trials? J Med Ethics, 32, 548-553
28. Caplan A (2007) Is it sound public policy to let the terminally ill access experimental medical innovations? Am J Bioeth, 7, 1-3
29. Anand G (2007) Saying no to Penelope. Wall Street Journal, May 1
30. Annas GJ (2007) Cancer and the constitution: choice at life's end. N Engl J Med, 357, 408-413
31. Davis MP (2006) Should experimental therapy be made available off-study for terminally ill patients? Lancet Oncol, 7, 531-532
32. Society for Clinical Trials Board of Directors (2006) The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients. Clinical Trials, 3, 154-157
33. Robertson JA (2006) Controversial medical treatment and the right to health care. Hastings Cent Rep, 36, 15-20
34. Gesme D (2007) Should terminally ill patients have the right to take drugs that pass phase 1 testing? No. Br Med J, 335, 479
35. Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 445-470 (D.C. Circuit Court 2006)
36. Vicini J (2008) US court rejects appeal seeking unapproved drugs. Reuters, January 14. http:// www.reuters.com/article/idUSN1441100420080114 (last accessed 26 August 2008); Access, Compassion, Care, and Ethics for Seriously Ill Patients Act (ACCESS Act), S.1956, 109th Congress (2005) and H.R. 6270, 110th Congress (2008)
37. Jacobson PD, Parmet WE (2007) A new era of unapproved drugs: the case of Abigail Alliance v. Von Eschenbach. J Am Med Assoc 297, 205-208
38. Society, Society opposes US legislation
39. Deyo RA, Patrick DL (2004) Hope or Hype: The Obsession with Medical Advances and the High Cost of False Promises. Amacom: New York
40. Henderson GE, Churchill LR, Davis AM et al. (2007) Clinical trials and medical care: defining the therapeutic misconception. PLoS Med, 4, e324
41. Mayer M (2008) Swimming upstream: an advocate reflects on cancer research and social realities. J Clin Oncol, 26, 2783-2786
42. Bender S, Flicker L, Rhodes R (2007) Access for the terminally ill to experimental medical innovations: a three-pronged threat. Am J Bioeth, 7, 3-6
43. Okie S (2006) Access before approval: a right to take experimental drugs? N Engl J Med, 355, 437-440
44. Edwards SJL (2006) Restricted treatments, inducements, and research participation. Bioethics, 20, 77-91
45. Freedman RS, Markman M (2007) Food and Drug Administration expanded access to treatment: implications for oncology patients. Cancer, 109, 2157-2160
46. Food and Drug Administration (FDA) (2006) Proposed rules for charging for investigational drugs and expanded access to investigational drugs for treatment use. http://www.fda.gov/ cder/regulatory/applications/IND-PR.htm (last access 27 August 2008)
47. Talbott MK (2007) The implications of expanding access to unapproved drugs. J Law Med Ethics, 35, 316-319
48. Nickerson RS (1998) Confirmation bias: a ubiquitous phenomenon in many guises. Rev General Psychol, 2, 175-220
49. Rhodes R (2005) Rethinking research ethics. Am J Bioeth, 5, 7-28
50. Emanuel EJ, Grady C (2006) Four paradigms of clinical research and research oversight. Camb Q Healthc Ethics, 16, 82-96